More recently, Wand and colleagues tested the therapeutic efficacy of a SOCS-1-silenced DC vaccine loaded with two tumour-associated antigens, survivin and MUC-1 in patients with relapsed acute leukemia (AL) after allogenic hematopoietic stem cell transplantation (allo-HSCT) [62]. Here, BIRC5 is linked to neoplasm.